Evidence map›Paper›PMID 42007255›Full record

ArticleBlood neoplasia2026

Targeting the G-protein-coupled estrogen receptor: a novel therapeutic strategy in cutaneous T-cell lymphoma.

Deniz Özistanbullu, Karola Bahrami, Monika Doll, Gabi Reichenbach, Martina Sarah Pöschl, Raphael Wilhelm, Nadja Zöller, Anke König, Pascal Spahn, Manuel Jäger and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Deniz ÖzistanbulluDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Karola BahramiDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Monika DollDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Gabi ReichenbachDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Martina Sarah PöschlDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Raphael WilhelmDepartment of Dermatology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany.
Nadja ZöllerDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Anke KönigDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Pascal SpahnDepartment of Dermatology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
Manuel JägerDepartment of Dermatology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany.
Sven R QuistClinic of Dermatology, Helix Medical Excellence Center Mainz, Mainz, Germany.
Theresia SchellerExperimental Pharmacology & Oncology Berlin-Buch GmbH, Berlin, Germany.
Lars WinklerExperimental Pharmacology & Oncology Berlin-Buch GmbH, Berlin, Germany.
Jan P NicolayDepartment of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
Bastian SchillingDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Roland KaufmannDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Markus MeissnerDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Johannes KleemannDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.
Stefan KippenbergerDepartment of Dermatology, Venereology and Allergology, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cutaneous T-cell lymphoma (CTCL) represents a heterogeneous group of non-Hodgkin lymphomas with limited curative treatment options. The pronounced male predominance in CTCL incidence suggests hormonal influences in disease pathogenesis, prompting investigation into estrogen receptor signaling pathways as therapeutic targets. Building upon previous evidence of tumor-suppressive roles of estrogen signaling via estrogen receptor β, we investigated the therapeutic potential of targeting the G-protein-coupled estrogen receptor (GPER) in CTCL models. We evaluated the antitumor effects of G-1, a selective GPER agonist, in CTCL cell lines and primary patient-derived malignant T cells using in vitro and in vivo approaches. G-1 demonstrated robust dose-dependent cytotoxic effects against CTCL cells, with notable selectivity, as healthy CD4

Identifiers

PMID42007255
PMCPMC13087468

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.